Skip to main content

01.12.2012 | Primary research | Ausgabe 1/2012 Open Access

Cancer Cell International 1/2012

Inhibition of breast cancer cell proliferation in repeated and non-repeated treatment with zoledronic acid

Cancer Cell International > Ausgabe 1/2012
Toni Ibrahim, Laura Mercatali, Emanuele Sacanna, Anna Tesei, Silvia Carloni, Paola Ulivi, Chiara Liverani, Francesco Fabbri, Michele Zanoni, Wainer Zoli, Dino Amadori
Wichtige Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1186/​1475-2867-12-48) contains supplementary material, which is available to authorized users.
Toni Ibrahim, Laura Mercatali contributed equally to this work.

Competing interests

The authors declare that they have no conflict of interests.

Authors’ contributions

TI, LM and DA conceived the study and, together with AT and FF, participated in its design. LM and MZ performed part of the experimental work. ES carried out the chemosensitivity tests, CL the western blot analyses, SC cell cycle and apoptosis analyses, and PU the molecular genetic studies. TI, LM, AT and ES contributed to manuscript drafting. WZ and DA critically revised the manuscript for intellectual content. All authors approved the final version of the manuscript.



Zoledronic acid is used to treat bone metastases and has been shown to reduce skeletal-related events and exert antitumor activity. The present in vitro study investigates the mechanism of action of Zoledronic Acid on breast cancer cell lines with different hormonal and HER2 patterns. Furthermore, we investigated the efficacy of repeated versus non-repeated treatments.


The study was performed on 4 breast cancer cell lines (BRC-230, SkBr3, MCF-7 and MDA-MB-231). Non-repeated treatment (single exposure of 168 hrs’ duration) with zoledronic acid was compared with repeated treatment (separate exposures, each of 48 hrs’ duration, for a total of 168 hrs) at different dosages. A dose–response profile was generated using sulforhodamine B assay. Apoptosis was evaluated by TUNEL assay and biomolecular characteristics were analyzed by western blot.


Zoledronic acid produced a dose-dependent inhibition of proliferation in all cell lines. Anti-proliferative activity was enhanced with the repeated treatment, proving to be statistically significant in the triple-negative lines. In these lines repeated treatment showed a cytocidal effect, with apoptotic cell death caused by caspase 3, 8 and 9 activation and decreased RAS and pMAPK expression. Apoptosis was not observed in estrogen receptor-positive line: p21 overexpression suggested a slowing down of cell cycle. A decrease in RAS and pMAPK expression was seen in HER2-overexpressing line after treatment.


The study suggests that zoledronic acid has an antitumor activity in breast cancer cell lines. Its mechanism of action involves the decrease of RAS and RHO, as in osteoclasts. Repeated treatment enhances antitumor activity compared to non-repeated treatment. Repeated treatment has a killing effect on triple-negative lines due to apoptosis activation. Further research is warranted especially in the treatment of triple-negative breast cancer.
Authors’ original file for figure 1
Authors’ original file for figure 2
Authors’ original file for figure 3
Authors’ original file for figure 4
Authors’ original file for figure 5
Authors’ original file for figure 6
Authors’ original file for figure 7
Authors’ original file for figure 8
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2012

Cancer Cell International 1/2012 Zur Ausgabe